Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Netarsudil

    Client Email Product

    Netarsudil

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    7
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    7
    API REF. PRICE (USD / KG)
    270,831

    API Market Place

    4
    INTERMEDIATES
    4
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    244.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    34
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    28
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Alcon Completes Acquisition of Aerie Pharmaceuticals
    Alcon Completes Acquisition of Aerie Pharmaceuticals

    https://www.businesswire.com/news/home/20221121005923/en

    BUSINESSWIRE
    22 Nov 2022
    Share Share
    Aerie Pharmaceuticals Announces New Employee Inducement Grant
    Aerie Pharmaceuticals Announces New Employee Inducement Grant

    https://www.businesswire.com/news/home/20220815005097/en

    BUSINESSWIRE
    15 Aug 2022
    Share Share
    Aerie Announces 1st Participant Dosed in COMET-3 Study of AR-15512
    Aerie Announces 1st Participant Dosed in COMET-3 Study of AR-15512

    https://www.businesswire.com/news/home/20220801005762/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan
    Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan

    https://investors.aeriepharma.com/news-releases/news-release-details/aerie-concludes-exclusive-license-agreement-santen-rhopressar

    PRESS RELEASE
    07 Dec 2021
    Share Share
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan
    Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan

    https://www.businesswire.com/news/home/20211012005106/en

    BUSINESSWIRE
    12 Oct 2021
    Share Share
    Meeting highlights from the Committee for Medicinal Products for Human Use
    Meeting highlights from the Committee for Medicinal Products for Human Use

    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020

    EMA
    13 Nov 2020
    Share Share
    Aerie Receives Positive CHMP Opinion for Roclanda®European Union
    Aerie Receives Positive CHMP Opinion for Roclanda®European Union

    https://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-receives-positive-chmp-opinion-roclandar#:~:text=Aerie%20Pharmaceuticals%20Receives%20Positive%20CHMP%20Opinion%20for%20Roclanda%C2%AE%20in%20the%20European%20Union,-11%2F13%2F2020&text=DURHAM%2C%20N.C.&text=The%20CHMP%20positive%20opinion%20is,decision%20on%20the%20Company's%20MAA.

    PRESS RELEASE
    13 Nov 2020
    Share Share
    Santen and Aerie Conclude Exclusive License Agreement for Rhopressa®
    Santen and Aerie Conclude Exclusive License Agreement for Rhopressa®

    https://www.businesswire.com/news/home/20201028005090/en

    BUSINESSWIRE
    27 Oct 2020
    Share Share
    Aerie Pharma Announces Successful Interim Data From Its Mercury 3 Clinical Trial
    Aerie Pharma Announces Successful Interim Data From Its Mercury 3 Clinical Trial

    https://www.businesswire.com/news/home/20200924005095/en

    BUSINESSWIRE
    24 Sep 2020
    Share Share
    Aerie Announces U.S. FDA Approval of its Athlone Production of Rhopressa
    Aerie Announces U.S. FDA Approval of its Athlone Production of Rhopressa

    https://www.businesswire.com/news/home/20200915005132/en/Aerie-Pharmaceuticals-Announces-U.S.-Food-and-Drug-Administration-Approval-of-its-Athlone-Ireland-Facility-for-Production-of-Rhopressa%C2%AE-netarsudil-ophthalmic-solution-0.02

    BUSINESSNEWS WIRE
    15 Sep 2020
    Share Share
    Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda
    Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda

    https://www.businesswire.com/news/home/20191203005049/en/Aerie-Pharmaceuticals-Submits-Marketing-Authorisation-Application-Roclanda%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESS WIRE
    03 Dec 2019
    Share Share
    Aerie’s netarsudil shows promise in Phase II trial in Japan
    Aerie’s netarsudil shows promise in Phase II trial in Japan

    https://www.clinicaltrialsarena.com/news/aerie-phaseii-netarsudil-study-data/

    CLINICAL TRIAL ARENA
    05 Nov 2019
    Share Share
    Medical Properties Trust to buy 10 hospitals for $700M
    Medical Properties Trust to buy 10 hospitals for $700M

    https://seekingalpha.com/news/3514317-medical-properties-trust-buy-10-hospitals-700m

    Liz Kiesche SEEKINGALPHA
    05 Nov 2019
    Share Share
    Aerie Pharma Announces +Ve Topline Results for Netarsudil Ophh Solution in Ph 2
    Aerie Pharma Announces +Ve Topline Results for Netarsudil Ophh Solution in Ph 2

    https://www.businesswire.com/news/home/20191105005217/en/Aerie-Pharmaceuticals-Announces-Positive-Topline-Results-Netarsudil/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    05 Nov 2019
    Share Share
    Xospata leads latest CHMP recommendations
    Xospata leads latest CHMP recommendations

    http://www.pharmatimes.com/news/xospata_leads_latest_chmp_recommendations_1302120

    Anna Smith PHARMATIMES
    21 Sep 2019
    Share Share
    EMA's CHMP Recommends Three New Medicines
    EMA's CHMP Recommends Three New Medicines

    https://www.raps.org/news-and-articles/news-articles/2019/9/emas-chmp-recommends-three-new-medicines

    Michael Mezher RAPS
    20 Sep 2019
    Share Share
    Aerie adds Vargas, once of Abbott, to medical affairs team
    Aerie adds Vargas, once of Abbott, to medical affairs team

    https://www.fiercebiotech.com/biotech/aerie-adds-vargas-once-abbott-to-medical-affairs-team

    Nick P. Taylor FIERCE BIOTECH
    27 Aug 2019
    Share Share
    Less than a year after Rhopressa launch, Aerie scores new glaucoma drug approval
    Less than a year after Rhopressa launch, Aerie scores new glaucoma drug approval

    https://endpts.com/less-than-a-year-after-rhopressa-launch-aerie-scores-new-glaucoma-drug-approval/

    Natalie Grover ENDPTS
    14 Mar 2019
    Share Share
    Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
    Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study

    http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-reports-topline-result-rhopressar

    PRESS RELEASE
    15 Aug 2018
    Share Share
    Aerie Announces Early Notification of FDA Acceptance of NDA Sub for Roclatan™
    Aerie Announces Early Notification of FDA Acceptance of NDA Sub for Roclatan™

    http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-early-notification-fda

    PRESS RELEASE
    27 Jul 2018
    Share Share
    Aerie Pharma Announces FDA Acceptance of NDA for Roclatan
    Aerie Pharma Announces FDA Acceptance of NDA for Roclatan

    https://www.businesswire.com/news/home/20180723005106/en

    BUSINESSWIRE
    23 Jul 2018
    Share Share
    Aerie Submits NDA to U.S. Food and Drug Administration for RoclatanTM
    Aerie Submits NDA to U.S. Food and Drug Administration for RoclatanTM

    http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-submits-new-drug-application-us-food-and-0

    PRESS RELEASE
    15 May 2018
    Share Share
    Aerie's Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic sol) 0.02%
    Aerie's Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic sol) 0.02%

    https://www.businesswire.com/news/home/20180430005006/en/Aerie-Pharmaceuticals-Announces-U.S.-Launch-Rhopressa%C2%AE-netarsudil

    BUSINESSWIRE
    30 Apr 2018
    Share Share
    Aerie Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution)
    Aerie Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution)

    http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-launch-rhopressar-netarsudil

    PRESS RELEASE
    30 Apr 2018
    Share Share
    FDA’s year-end approvals take annual tally to 46
    FDA’s year-end approvals take annual tally to 46

    http://www.pmlive.com/pharma_news/fdas_year-end_approvals_take_annual_tally_to_46_1215003

    Phil Taylor PMLIVE
    02 Jan 2018
    Share Share
    Aerie bags early OK for its self-described blockbuster glaucoma drug Rhopressa
    Aerie bags early OK for its self-described blockbuster glaucoma drug Rhopressa

    https://endpts.com/aerie-bags-an-early-ok-for-its-self-described-blockbuster-glaucoma-drug-rhopressa/

    John Carroll ENDPTS
    18 Dec 2017
    Share Share
    RHOPRESSA® for topical ophthalmic use Initial U.S. Approval: 2017
    RHOPRESSA® for topical ophthalmic use Initial U.S. Approval: 2017

    http://investors.aeriepharma.com/static-files/d78e4f47-803b-4174-8f89-ddcc200e3972

    PRESS RELEASE
    18 Dec 2017
    Share Share
    Aerie Announces USFDA Approval Rhopressa®netarsudil ophthalmic solution 0.02%
    Aerie Announces USFDA Approval Rhopressa®netarsudil ophthalmic solution 0.02%

    http://investors.aeriepharma.com/news-releases/news-release-details/aerie-pharmaceuticals-announces-us-fda-approval-rhopressar

    PRESS RELEASE
    18 Dec 2017
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search